OneSkin

Predicting longevity using polygenic risk scores

Latest articles

Exclusive video interview with Erin Sharoni of JUVICELL

We talk fasting, lifespan and longevity supplements with JUVICELL's co-founder, Erin Sharoni. Recently, we were excited to cover the launch of brand-new longevity supplement JUVICELL,...

Longevity supplement innovator soft-closes $5.5m

Ponce de Leon: the longevity supplement company behind Rejuvant could raise up to $15m in current series B round. Ponce de Leon Health, a company...

Swiss longevity company builder launches

Swiss-based Maximon already moving forward with companies focused on precision supplements and personalised longevity advice. Already touted as a hotbed of longevity innovation, Switzerland is...

New aging clock is a key longevity tool

A new aging clock that's close to the theoretical limit of accuracy boasts unprecedented precision and offers new insights into how the aging process...

Most read

New NAD+ boosting longevity supplement hits the market

Elevant Prime dietary supplement contains a “high purity” form of NMN that has completed safety and toxicology testing. New York based health and wellness brand...

JUVICELL sets sights on lifespan and healthspan

Ten ingredients, one capsule. JUVICELL is on a mission to deliver an all-in-one longevity supplement. Far from just supplementing their diet to ensure an adequate...

Is nicotinamide riboside a safe and effective way to combat aging?

ChromaDex executive highlights the importance of clinical studies to prove the benefits of NAD+ boosting compound. ChromaDex is the company behind the popular healthy aging...
Apollo Neuro

Editor's picks

Exclusive video interview with Erin Sharoni of JUVICELL

We talk fasting, lifespan and longevity supplements with JUVICELL's co-founder, Erin Sharoni. Recently, we were excited to cover the launch of brand-new longevity supplement JUVICELL,...

Longevity supplement innovator soft-closes $5.5m

Ponce de Leon: the longevity supplement company behind Rejuvant could raise up to $15m in current series B round. Ponce de Leon Health, a company...

Swiss longevity company builder launches

Swiss-based Maximon already moving forward with companies focused on precision supplements and personalised longevity advice. Already touted as a hotbed of longevity innovation, Switzerland is...
OneSkin

Health and disease prediction scores could become a routine personal genomics risk prediction method for lifelong health planning, disease prevention and patient stratification.

Many commonly diagnosed disorders are polygenic, meaning they are caused by multiple disease-associated gene variants. Polygenic risk scores (PRS) use genetic data to assess the heritable risk of developing a disease by combining the risk of these different gene variants to generate an individual risk score. This precision medicine approach of PRS can greatly improve the prediction of disease development and disease outcomes, including age-related diseases, where prevention and early intervention are essential for healthy aging.

Longevity.Technology: Prevention is better than cure, and early prevention is even better. PRS is already a powerful screening tool that can prevent patients undergoing expensive or invasive tests, so as it moves into the clinic, its scope could extend to screening for longevity, allowing for personalised and precise therapies to maximise healthspan and lifespan to be deployed. Given the recent rise in personal genomics companies, the drop in the prices of genotyping and the rise of personalised medicine, personalising biomarker analysis means PRS has an important part to play in the Longevity field. Polygenic risk scores could be as key as conventional clinical risk predictors, with a single genetic test offering information on the entire disease spectrum.

Although certain gene variants may contribute to disease development and progression, their individual contribution is, in most cases, relatively small. The enhanced predictive value of PRS lies in the summation of individual risk factors and the integration of environmental risk factors. Large scale whole-genome sequencing studies are required to develop and refine PRS as they are based on reoccurring gene patterns in patients to achieve high predictive value. Once established, PRS may provide the key to early disease prevention and help extend the healthspan of carriers of disease-associated gene variants.

Osteoporosis is a common disorder in the elderly and is generally assessed by a costly bone mineral density scan. However, those with genetic predispositions, including carriers of GP6C and EN1 variants, have an increased risk of reduced bone mineral density. Forgetta et al. demonstrated that incorporating PRS in the assessment of the 10-year probability of major osteoporotic fracture risk screening can reduce the proportion of individuals undergoing bone marrow density scan by 41% without any appreciable reduction in the capacity to correctly identify individuals requiring treatment [1].

These findings show that genetic prediction not only can be beneficial for large scale screening programmes, but can also reduce healthcare costs by avoiding costly procedures.

Although type 1 diabetes is associated with a significant heritable risk, its development is difficult to predict. Ferrat et al. demonstrated that PRS could accurately identify children at high risk of developing type 1 diabetes; thus, early intervention could be achieved in individuals at risk of developing the disease whilst those less likely to develop type 1 diabetes can be spared from the unnecessary toxicities of immunosuppressive drugs [2].

In breast cancer, there are multiple gene variants predisposing carriers to a higher risk of developing the disease. Individually, these variants – often interfering with DNA repair processes – have an odds ratio ranging from 0.85 to 1.20. However, their combined impact on breast cancer risk is significantly larger, and the predictive value of many gene variants is also greater.

“By improving identification of these women at high risk of breast cancer, it could serve as a new tool for personalised, risk-based breast cancer screening,” said Dr Samuli Ripatti, lead author of the study [3].

 


 

“Germline genetic variants are attractive biomarkers because they are stable throughout the lifetime and could potentially provide information about disease predisposition from an early age,”

 


 

In schizophrenia, a disorder usually diagnosed in late adolescence or early adulthood, the 22q11DS gene variant is associated with a 20-25% risk of developing the disease. In a recent study, Davies et al. used PRS and identified two novel associations between schizophrenia and schizophrenia-related phenotypes, suggesting that cognitive decline observed in schizophrenia may be caused by common risk variants. By identifying high-risk patient populations, better treatment and interventions can be integrated into the treatment plan, thereby prolonging patient healthspan [4].

In coronary artery disease, considerable progress has been made in the identification of disease-associated genetic variants, including single nucleotide polymorphisms. By adding PRS to pooled cohort equations for coronary artery disease, the authors found a significant increase in the predictive accuracy of coronary artery disease incident and improved patient stratification in a proportion of the cohort [5].

“Germline genetic variants are attractive biomarkers because they are stable throughout the lifetime and could potentially provide information about disease predisposition from an early age,” said Dr Ioanna Tzoulaki, lead author of the study.

The predictive value of PRS has immense potential to significantly improve healthspan by enabling early disease detection or predicting disease development, thus, enabling early intervention. As genotyping becomes increasingly cost-effective and personalised medicine increasingly important, PRS could play a significant role in disease monitoring and lifelong health care. Although PRS has a promising Longevity future, many genetic diseases are also affected by environmental factors and complex interactions, meaning that there is still much work to do for the full benefits to be realised in a clinical setting.

[1] https://tinyurl.com/y5oclqmm
[2] https://journals.plos.org/plosmedicine/article?id=10.1371/journal.pmed.1003152
[3] https://www.nature.com/articles/s41591-020-1103-1
[4] https://www.nature.com/articles/s41591-020-1103-1
[5] https://jamanetwork.com/journals/jama/fullarticle/2761088

Image credit: Tatyana Soares / Shutterstock
Christos Evangelou
Since the completion of his undergraduate and doctoral studies in Molecular Biosciences, Christos has been working in the medical communications industry, driven by his passion for communicating sciences. Apart from helping researchers to publish their studies, Christos writes articles related to sciences and medicine.
OneSkin

Most popular

New NAD+ boosting longevity supplement hits the market

Elevant Prime dietary supplement contains a “high purity” form of NMN that has completed safety and toxicology testing. New York based health and wellness brand...

JUVICELL sets sights on lifespan and healthspan

Ten ingredients, one capsule. JUVICELL is on a mission to deliver an all-in-one longevity supplement. Far from just supplementing their diet to ensure an adequate...

Is nicotinamide riboside a safe and effective way to combat aging?

ChromaDex executive highlights the importance of clinical studies to prove the benefits of NAD+ boosting compound. ChromaDex is the company behind the popular healthy aging...

NAD+ and metformin: AgelessRx’s anti-aging platform

Personalised longevity medicine is the top goal for AgelessRx. In November we spoke to Anar Isman, the Co-founder & CEO of AgelessRx, about PEARL, the...
Apollo Neuro

Related articles

New aging clock is a key longevity tool

A new aging clock that's close to the theoretical limit of accuracy boasts unprecedented precision and offers new insights into how the aging process...

Skin patch reads both cardiovascular and metabolic biomarkers

UC San Diego researchers create the first wearable device for simultaneous monitoring of haemodynamic and biochemical biomarkers. Biohackers take note! Engineers at the University of...

International Day of Women and Girls in Science

As we celebrate International Day of Women and Girls in Science, here are just a few of the names to be found in our...

It’s time to sit up and take notice of mitochondria

CohBar CEO on the development of a “true portfolio” of mitochondria based therapeutics. US biotech company CohBar is developing mitochondria-based therapeutics for the treatment of...

At-home diagnostic system sees growth in older users

Tyto Care conducted more than 650,000 telehealth exams last year as COVID-19 drives increased uptake, including in senior care environments. The COVID-19 pandemic has driven...
OneSkin